Abstract
Invasive fungal infections (IFIs) can cause significant morbidity and mortality in patients after haematopoietic stem cell transplantation. The two most notorious pathogenic fungal species in this group of patients are Candida and Aspergillus. Risk factors for IFIs include: prolonged neutropaenia; fungal overgrowth and conditioning regiment-related mucositis; graft versus host disease; and steroid therapy. Clinical manifestations can be protean, and radiological changes are frequently nonspecific. Diagnostic methods include culture- and nonculture-based techniques. Some experts recommend IFI prophylaxis in the high-risk groups, such as patients with severe graft versus host disease who require prolonged immunosuppressive therapy or patients with a previous history of aspergillosis. Treatment options include therapy with azoles, including the newer agent voriconazole, amphotericin and caspofungin.
MeSH terms
-
Amphotericin B / administration & dosage
-
Amphotericin B / therapeutic use
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / diagnosis
-
Aspergillosis / drug therapy*
-
Aspergillosis / prevention & control
-
Bone Marrow Transplantation*
-
Candidiasis / diagnosis
-
Candidiasis / drug therapy*
-
Candidiasis / prevention & control
-
Caspofungin
-
Drug Administration Schedule
-
Echinocandins
-
Humans
-
Lipopeptides
-
Peptides, Cyclic / administration & dosage
-
Peptides, Cyclic / therapeutic use
-
Postoperative Complications / diagnosis
-
Postoperative Complications / drug therapy*
-
Postoperative Complications / prevention & control
-
Premedication*
-
Pyrimidines / administration & dosage
-
Pyrimidines / therapeutic use
-
Randomized Controlled Trials as Topic
-
Triazoles / administration & dosage
-
Triazoles / therapeutic use
-
Voriconazole
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Peptides, Cyclic
-
Pyrimidines
-
Triazoles
-
Amphotericin B
-
Caspofungin
-
Voriconazole